Stock Analiz

Neurogene Inc. NGNE

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$23.93Market cap $495M
Open the interactive analysis →

Neurogene Inc. (NGNE) is a healthcare company listed in the US with a market value of about $495M.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -28%.

About Neurogene

Neurogene is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $25M in 2018 to $925000 in 2024, a decline of about 42.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 61% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-19.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-8123.7%
ROIC (5-yr avg.)-28.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$925000$0————$25M——
Net income-$90M-$75M-$36M-$55M-$61M-$33M-$69M-$32M-$50M-$37M
Free cash flow-$78M-$71M-$52M-$55M-$51M-$27M-$16M-$32M-$45M-$31M
EPS (diluted)$-4.24$-4.28—$-1.04$-1.10$-0.64$-2.57$-1.34$-2.14$-1.96
Net margin—-8123.7%—————-126.3%——
ROIC-37.6%-25.6%-21.9%——-13.1%-39.3%-35.5%-40.8%-26.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $77.62, 224% above the current price; targets range from $46.00 to $166.00; the consensus rating is “Strong buy”; expected EPS is $-5.00 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Neurogene pay a dividend?

Not currently.

Is Neurogene a good stock to buy?

We do not give buy or sell advice. Neurogene scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.